

Press Release

For Immediate Release

New Delhi, 19th April, 2006

Panacea Biotec Inaugurates Pharmaceutical Formulation Plant at Baddi

Panacea Biotec, India's leading research based health management company has commenced production in their new Pharmaceutical Formulation Plant at Baddi, Himachal Pradesh with an investment of around Rs. 45 Crore. This plant is in compliance with global standards including US FDA and UK MHRA, SA MCC and WHO cGMP.

Situated amidst picturesque surroundings in the state of Himachal Pradesh, Panacea Biotec's facility in Baddi is spread over 70,000 sqm. and it will be catering to the manufacturing of oral & topical pharmaceutical finished dosage forms. The facility is equipped with modern equipment and machinery to meet the regulatory standards of the US, European & South African markets.

The Baddi facility, with high capacities and scope for future expansion is designed to produce various formulations viz. tablets, capsules, ointments and liquids. The facility has an installed capacity of 900 million tablets, 120 million capsules, 12 million ointment/gel tubes and 1.2 million litres Liquid Orals per annum.

Inaugurating the plant, Mr. Rajesh Jain, Joint Managing Director, stated "Our Baddi facility is a showcase of the latest in modern technology and is equipped with ultra modern and sophisticated machines and integrated packaging lines. The plant will produce high quality healthcare products accessible and affordable for all. This facility will give a competitive edge to the company as we continue to innovate and step up our growth strategy. This new manufacturing facility will support our future growth and facilitate rapid rollout of new products".

About Panacea Biotec Ltd.

Panacea Biotec, ranked third amongst biotechnology companies in the country, manufactures and markets a broad range of branded formulations and biotechnology based products of international quality.

In line with its mission "In Support of Life", Panacea Biotec focuses on vaccines and innovative prescription products in important therapeutic areas like pain management, diabetes management, renal disease management, anti-osteoporotic, anti-tubercular & anti-bacterials.

Panacea Biotec has collaborations with leading Global pharmaceutical companies and reputed International Institutions, such as Chiron Corporation, USA, Heber Biotec, SA, Cuba, Becton Dickinson, USA, Solvay, Netherlands, Cambridge Biostability, UK and National Institute of Health, USA.

In India the company has R&D alliances with National Research & Development Corporation, Jawahar Lal Nehru University and Punjab University.

Recently the company has also concluded its \$100 million foreign currency convertible bonds issue.

Panacea Biotec has a license agreement with Biotechnology Consortium of India (BCI) for manufacturing & marketing of anti-anthrax vaccine developed by JNU and the company has also entered into arrangements with National Institute of Immunology (NII) for licensing of technology and processes for the production of tissue culture-derived, formalin-inactivated Japanese Encephalitis Candidate Vaccine.

For further details please contact:

Ritu Jain

Manager Corporate Communications

Mobile: 9811316770, Email: ritujain@pblintranet.com